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Abstract
Background: Management of Severe Acute Malnutrition (SAM) plays a vital role in achieving global child survival targets.
Effective treatment programmes are available but little is known about longer term outcomes following programme
discharge.
Methods: From July 2006 to March 2007, 1024 children (median age 21.5 months, IQR 15–32) contributed 1187 admission
episodes to an inpatient-based SAM treatment centre in Blantyre, Malawi. Long term outcomes, were determined in a
longitudinal cohort study, a year or more after initial programme discharge. We found information on 88%(899/1024).
Results: In total, 42%(427/1024) children died during or after treatment. 25%(105/427) of deaths occurred after normal
programme discharge, .90 days after admission. Mortality was greatest among HIV seropositive children: 62%(274/445).
Other risk factors included age ,12 months; severity of malnutrition at admission; and disability. In survivors, weight-for-
height and weight-for-age improved but height-for-age remained low, mean 22.97 z-scores (SD 1.3).
Conclusions: Although SAM mortality in this setting was unacceptably high, our findings offer important lessons for future
programming, policy and research. First is the need for improved programme evaluation: most routine reporting systems
would have missed late deaths and underestimated total mortality due to SAM. Second, a more holistic view of SAM is
needed: while treatment will always focus on nutritional interventions, it is vital to also identify and manage underlying
clinical conditions such as HIV and disability. Finally early identification and treatment of SAM should be emphasised: our
results suggest that this could improve longer term as well as short term outcomes. As international policy and
programming becomes increasingly focused on stunting and post-malnutrition chronic disease outcomes, SAM should not
be forgotten. Proactive prevention and treatment services are essential, not only to reduce mortality in the short term but
also because they have potential to impact on longer term morbidity, growth and development of survivors.
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Background
Severe acute malnutrition (SAM) is a major global public health
problem [1],[2]. It includes two forms of malnutrition, oedematous
malnutrition (kwashiorkor) and severe wasting (low weight-for-
height and/or low mid upper arm circumference) [3]. Severe
wasting alone affects 18.7 million children (95% CI 14.2 to 23.2
million) aged under 5 years and is responsible for over half a
million deaths per year (7.4 to 7.8% of total under-5 child deaths)
[4]. Treating SAM thus has an important role to play towards
global health initiatives such as Millennium Development Goal 4,
decreasing child mortality [5]. For treatment services to improve
their effectiveness and impact, it is vital that they are informed by
high quality evidence.
Whilst there are no universal performance targets for SAM
treatment programmes, there are widely acknowledged minimum
standards such as those set by the ‘SPHERE’ humanitarian
charter [6]. The latest version of SPHERE released in 2011
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suggests that overall therapeutic feeding programme mortality
should not exceed 10%, less than 15% should default, and over
75% of discharges should have recovered - defined as ‘‘free from
medical complications; regained appetite; achieved and main-
tained appropriate weight gain without nutrition-related oedema,
(e.g. for two consecutive weighings)’’ [6]. Such outcomes are
certainly achievable, especially in well run ‘Community Manage-
ment of Acute Malnutrition’ (CMAM) programmes which
emphasize high population coverage, proactive case-finding, and
early treatment [7]. (SPHERE emphasises that the interpretation
of outcomes should take into account programme type: pro-
grammes which implement outpatient care alone should expect
better outcomes than those which include inpatient care, the latter
usually having a sicker and more vulnerable patient group).
However, even if the SPHERE targets are achieved, it is important
for managers, policy makers and funders to appreciate that these
are short term outcomes, after a median of some 40 days of
treatment. They do not necessarily reflect subsequent child
survival and morbidity outcomes. The true public health impact
of an intervention is also determined by how the discharged
children fare in the longer term.
There is limited data on long term outcomes following discharge
from SAM treatment. The few studies that have looked at this are
mostly old, pre HIV and even pre current definitions of SAM [8].
This represents an important knowledge gap. Our primary aim in
this study was to follow up patients over a year after their
treatment for SAM to describe the longer term mortality and
growth outcomes. A secondary aim was to identify key risk factors
for good/poor long term outcomes, particularly those which might
be amenable to change or which would help identify high risk
individuals for more targeted future support. By doing this, our
goal is to inform improvements in future treatment services.
Methods
Ethics Statement
This follow-up study was approved by the Malawi College of
Medicine Research and Ethics Committee (Reference P.03/04/
236). Home visits followed the example of a previous study based
on MOYO [9] and had an added advantage of potential clinical
benefit i.e. if any problems were identified, the carer was advised
and where necessary referred.
Study Design
This was a prospective cohort study, arising from an RCT
(ISRCTN 19364765) described in detail elsewhere [10]. Briefly,
the ‘ProNut study’ had enrolled malnourished children in a trial
examining the efficacy of a prebiotic/probiotic mixture (Synbiotic
2000ForteTM) added to ready-to-use therapeutic food during SAM
treatment. No significant effects were found.
Study setting
MOYO nutrition ward, Queen Elizabeth Hospital, Malawi.
This serves a catchment population of both urban and rural
Blantyre district. At the time there were no community
programmes for SAM active in the district, so: no community
mobilization; no proactive identification of SAM cases; no sub-
classification into ‘complicated’ and ‘uncomplicated’ SAM [11].
Children diagnosed with SAM (either at local health centres or in
the paediatric admissions area of Queen’s hospital) were all
referred for inpatient care.
Anti-retroviral (ARV) treatment for HIV had been available in
Queen’s Hospital since 2004, and the process of scaling up and
decentralizing was happening at the time of this study. Whilst
ARVs were always available, guidance at the time was for children
newly diagnosed with HIV to start ARVs if meeting stage 3 or 4
(WHO classification) which included failure to respond to
nutritional therapy [12]. As a result many would not have been
considered for ARVs until 1–2 months after presenting with SAM,
and those with good nutritional recovery not be eligible unless
another staging criteria met. From October 2006 we were able to
obtain CD4 counts which also informed the decision to start
ARVs. Co-trimoxazole prophylaxis was provided from admission,
and advised to be continued indefinitely.
Participants
Cohort subjects were children admitted to MOYO nutrition
ward for inpatient care from the 12th July 2006 to 9th March 2007.
This was the ProNut recruitment period and included both dry
(July to November) and rainy seasons (December to March).
Whilst not every carer consented to their child’s enrolment into
ProNUT, almost all answered a detailed baseline questionnaire.
Admission criteria to MOYO followed Malawi 2007 national
guidelines [13]. These defined SAM as weight-for-height ,70%
median (NCHS growth references) and/or mid upper arm
circumference ,110 mm and/or oedematous malnutrition. Be-
cause of the inpatient-only set-up with children self-presenting to
care, it is likely that most would have been towards the
‘complicated’ end of the SAM spectrum [11]. However, since
our patient assessment at the time did not include an appetite test,
an unknown (but likely small) proportion would have had
‘uncomplicated’ SAM - which in today’s treatment programmes
would be treated at home [2].
Children who were successfully cured (defined as two consec-
utive visits at above 80% weight-for-height, no oedema, clinically
stable) in MOYO’s combined inpatient/outpatient programme
were asked to return for a ward-based review on the 1 year
anniversary of their cure date. Non-cures and those failing to
return for assessment were followed-up at their home by a mobile
team comprising of a study nurse and driver. They used a verbal
address obtained from carers during the admission. The mobile
team were usually able to determine outcome information at first
field visit, and only rarely needed to return if nobody was available
to report on what had happened to a child.
Variables
The main study outcome was to describe longer term post-
treatment survival. This was defined as the child being seen or
reliably reported to be alive at $1year after the original discharge
date from MOYO. Deaths were subdivided into short term (whilst
still an inpatient on MOYO); medium term (within the 1st 90 days
of admission but after inpatient care); longer term (defined as
death.90 days following programme admission). Ninety days was
chosen to be consistent with the upper limits of time normally
spent in therapeutic feeding; 3 weeks of inpatient care and 10
weeks in the ‘outpatient therapeutic programme’ (OTP).
We also assessed long term growth as a secondary outcome.
Weight-for-height, weight-for-age, and height-for-age z-scores
were all assessed and compared with sibling controls. Sibling
controls were identified at home visit and were defined as any
child born to the same mother and living in the same household.
We measured all siblings present at the time of follow-up visit but
due to limited resources were not able to return for a second visit if
any live siblings were away from the household at the original visit.
Additional variables were assessed at original admission to
MOYO and are available with complete data collection sheets
http://discovery.ucl.ac.uk/1306755/1/1306755.pdf [14]. They
included clinical history; clinical signs assessed by a doctor or
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study clinical officer; family and socioeconomic status; HIV status
(positive/negative/unknown); HIV clinical staging according to
WHO criteria [12].
Data Sources/measurement
During the initial ward admission, weight was measured using
on Tanita 1582 digital scales, accurate to 20 g and checked daily.
Length was measured to the nearest 1 mm on locally made
boards. Baseline measurements were recorded by two independent
observers, according to research standard protocols [15]. At
follow-up, the same scales were used but with a portable Leicester
height board, suitable for field use.
HIV testing was done on an opt-out basis as a routine part of
ward protocols. It involved two ELISA rapid tests (Determine
HIV-1/2 [Abbott Laboratories, USA] and Uni-Gold HIV
[Trinity Biotech PLC, Ireland]), with a third (Hema Strip HIV
1/2 [Chembio Diagnostic System Inc, USA] or SD-Bioline HIV
1/2 [Standard Diagnostics Inc, Korea]) in case of discordant
results. PCR for definitive diagnosis in children younger than 18
months of age was unavailable.
Study Size
The RCT in which the cohort was nested determined the
sample size [10]. To give an idea of the effect size that could be
confidently detected, the original ProNut sample size of 400 per
group was large enough, at 95% significance, 80% power, and
accommodating 100 losses to follow-up, to detect an inter-group
difference of 65% vs. 75% cure. With 1024 patients analysed in
FUSAM (more than in ProNUT since not all consented for
randomization and some died before the ProNut intervention
began) sample size would have been sufficient for most clinically
important exposures.
Statistical methods
Data were entered in EpiData 3.1 (EpiData Association,
Odense, Denmark, 2003–4). Check files helped ensure high
quality data entry, e.g. by checking that variables were in-range
and consistent with related variables. Key data (anthropometry,
dates, final outcomes, HIV status) were double entered. Unusual
results, such as a long time to final outcome, were cross checked
against original patient files.
Main analyses were performed using Stata Intercooled 10.0TM
(StataCorp LP, USA). Kaplan-Meier time-to-death curves are
presented as ‘step-up’ curves in accordance with suggested best
practice [16]. Multivariable analysis was done using Cox
regression. Because survival curves for HIV seropositive and
seronegative children violated the proportional hazards assump-
tion (confirmed by a formal test using Schoenfeld residuals),
complex multivariable analyses in our final results table are
presented stratified by HIV. Other key variables (admission
oedema, admission age, admission MUAC, admission WAZ) did
not violate the assumption. The ‘exactp’ option within Stata’s ‘stcox’
command was specified in all reported regression models.
Chi-square tables and approximate confidence limits for relative
risk were used to examine categorical data using StatCalc (CDC,
Atlanta, USA, 1993). Where cell numbers are small, Fisher exact
results are noted.
Quantitative variables
Z-scores were calculated from weight, height/length, age and
sex variables using ENA for SMART software, version October
2007 [17]. Lower (more negative) z-score imply more severe
malnutrition. Since children were admitted on the basis of NCHS
references, we felt it appropriate to analyse using NCHS
references. Given our research-standard measurement protocols
using two independent observers, baseline extreme Z-scores were
assumed to be real and not excluded [15]. However, with greater
potential for error associated with field-based work at the final
FuSAM visits, extreme final z-scores were considered more likely
to be measurement errors than a child who is truly very small or
very large. Following standard criteria [17], individuals with
extreme z-scores on follow-up were thus excluded from anthro-
pometry-related analysis: weight-for-height z-scores, WHZ
(NCHS) ,24 or .+6 or weight-for-age z-score, WAZ (NCHS)
,26 or .+6 or height-for-age z-score HAZ (NCHS) ,26 or .+
6.
For survival analysis and Cox regression, time 0 was the date of
admission to MOYO. Time to FuSAM follow-up for other
patients was calculated in days by subtracting date of admission
from date of final outcome (alive, dead or unknown/other). If
patients died within hours of admission, their length of stay was
counted as 0.5 days so that they would still contribute to the final
model.
Results
Over the eight month study period a total of 1,024 children
contributed to 1,187 malnutrition admission episodes. Final
outcome information was found on 889/1024(87%). Of the
135(13%) with no 1-year outcome: 45/135(33%) could not be
traced at the address given; 42(31%) did not give an address;
31(23%) had missing notes; 7(5%) lived too far away for the
outreach team to visit; 10(7%) had an outcome but at less than a
year. Outcomes are summarized in figure 1.
A total of 462/1024(45%) children were known to be still alive
at a year or more after discharge from treatment. Long term
survival was greatest amongst those who had been successfully
cured following initial treatment. Of 471 discharged from the
OTP as nutritionally cured, 365(77%) were still alive at a year or
more after their first admission. Of the 427/1024(42%) who died,
most did so early on in programme: 238/427(56%) of deaths were
during initial inpatient treatment. Most deaths, 274/427(64%),
were among children with underlying HIV infection. Differently
expressed, 274/445(62%) of known seropositive children died
while a total of 77/459(17%) of known seronegative children died.
Kaplan-Meier failure curves in figures 2 and 3 further
illustrate the probability of death during different time periods.
These include 1003 children: we could not plot the remaining 21/
1024(2.1%) since the date of final outcome was not known.
Median time from initial admission to final outcome was 287 days,
IQR 11 to 529. The steep initial slope of the curve highlights the
fact that most deaths happened soon after admission to
programme; median time to death was 10 days, IQR 3 days to
69 days. 278/427(65%) of deaths occurred within 30 days of
admission. Failure curves by HIV serostatus (figure 3) highlight
the significant adverse impact of HIV. For both HIV negative and
positive patients, most deaths occurred soon after admission.
However, they soon plateau for HIV negative patients but
continued to rise for those with HIV. The Log-rank test for the
difference between HIV negative and positive children was p,
0.0001.
Table 1 shows the baseline profile of the cohort according to
children’s final outcome. Further details are available online [14].
Because admissions at the time were based on NCHS growth
references, NCHS z-scores were used for subsequent calculations.
To enable future researchers to compare their data against ours we
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Figure 1. FuSAM study flow chart - all admissions to MOYO. (OTP= ‘Outpatient Treatment Programme’ – the outpatient part of treatment; T/
F = transfer out to different programme). ‘Still sick’ children were seen or reported to be clinically unwell at follow-up but details were not always
known.
doi:10.1371/journal.pone.0096030.g001
Figure 2. Kaplan Meier failure curve, all patients.
doi:10.1371/journal.pone.0096030.g002
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also however present admission anthropometry calculated using
WHO growth standards [18] (Table S1)
Key observations are that: children who died were younger than
those still alive at 1 year; kwashiorkor (oedematous malnutrition)
was the dominant type of SAM but risk of death was lower than in
non-oedematous SAM; children who were more malnourished
(lower z-scores); at baseline were more likely to die; HIV was
prevalent and HIV-associated mortality was high, especially with
advanced disease (as indicated by low CD4 count); disability -
mostly neurodisability such as cerebral palsy - was common and
deaths among disabled children were high. Another observation
was the large number of children who, according to their personal
health record (health ‘‘passport’’) or carer, were seen in an
outpatient clinic in the six months prior to SAM admission,. In
addition, many of these were seen for symptoms potentially
Figure 3. Kaplan Meier failure curves, by HIV serostatus. The tables below figures 2 and 3 show numbers at risk at the beginning of a
particular time period. Deaths are in parentheses. Numbers at risk are not simply those previous at-risk minus deaths. Other outcomes also result in
children being removed from further analysis (being ‘censored’). With this denominator change, the y-axis is mortality probability rather than
percentage. Whilst our main outcomes focus is on the first year post-discharge, for completeness, data is presented until the last child’s follow-up.
doi:10.1371/journal.pone.0096030.g003
Table 1. Patient profile at baseline (initial admission), by final outcome.
Characteristic Subcategory
Death in 1st 90 days
(Inpatient or
outpatient) (n = 322)
Later death
(n = 105)
Alive at $1 year
post admission
(n = 462) ALL (n = 1024)
Basic Demographics Age in months (median, IQR) 19.4 (13 to 30) 18.8 (12 to 29) 23.3 (17 to 34) 21.5 (15 to 32)
Boys 156/322 (48%) 66/105 (63%) 251/462 (54%) 543/1024(53%)
Type of SAM Kwashiorkor{ 175/322 (54%) 45/105 (43%) 383/462 (83%) 697/1024(68%)
Severe wasting 135/322 (42%) 55/105 (52%) 69/462 (15%) 275/1024 (27%)
Anthropometry
(z-scores)
Weight-for-height (WHZ) 22.77 (1.2) 22.65 (1.2) 21.92 (1.2) 22.25 (1.3)
Weight-for-age (WAZ) 24.13 (1.1) 24.30 (1.1) 23.18 (1.2) 23.59 (1.3)
Height-for-age (HAZ) 23.43 (1.4) 23.88 (1.3) 23.03 (1.4) 23.23 (1.4)
HIV HIV seronegative 57 (18%) 20 (19%) 315 (68%) 459 (45%)
HIV seropositive 191 (59%) 83 (70%) 139 (30%) 445 (43%)
HIV unknown 74 (23%) 2 (2%) 8 (2%) 120 (12%)
Clinical Disability (any) 24/282 (9%) 9/102 (9%) 22/453 (5%) 60/938 (6%)
Outpatient episodes (last 6 months) 233/253 (92%) 90/98 (92%) 396/440 (90%) 797/884 (90%)
Outpatient episodes (last 6 months,
symptoms suggestive of malnutrition)
60/254 (24%) 26/97 (27%) 84/437 (19%) 187/882 (21%)
{Numbers with kwashiorkor plus numbers with severe wasting = 972 rather than 1024: the remaining 52 patients had complicated moderate wasting. These children
were treated according to exactly the same protocols as those with SAM and hence are included in the follow-up study.
doi:10.1371/journal.pone.0096030.t001
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consistent with SAM (e.g. ‘‘swelling’’; ‘‘severely thin’’ or similar
noted in health passport’’).
Risk factors for mortality were further explored using multivar-
iable Cox Regression in Table 2. Adjusting for age, oedema and
HIV, low baseline MUAC, WHZ and WAZ are all strongly
associated with death. Low HAZ is of borderline significance.
Children with oedematous malnutrition were significantly less
likely to die than those without. Though the youngest children
below 12 months of age were significantly more likely to die, there
was no clear age-related risk gradient among older children. HIV
stands out as having the greatest adverse impact, an adjusted
hazard ratio of 4.03(95% CI 3.08 to 5.25). Deaths among children
whose HIV serostatus was unknown were especially high.
Table 3 shows clinical and social factors which might plausibly
explain mortality. What is notable here is that after adjusting for
baseline anthropometry, very few factors remain as independent
predictors of death. Disability stands out as strongly and
significantly associated with death in HIV negative patients, and
only just outside the p,0.05 threshold for HIV positive patients.
Severe anaemia (PCV,10) was also associated with increased risk
of death, but in HIV positive patients only.
Finally, Figure 4 shows the final anthropometry of the children
who had received treatment on the MOYO ward, compared to
sibling controls. Median birth order of the MOYO children was
2nd born. 184 of the ex-MOYO children had one or more siblings
measured and with valid anthropometric z-scores: 111 had only
one sibling; 54 had two siblings, 18 had three siblings and one had
four siblings (total 277 sibling controls). 12 sibling WHZ scores, 65
WAZ scores and 25 HAZ scores were excluded as extreme by our
cleaning process. Over 90% of siblings were reported as never
having had SAM themselves. Several points are of note. First is the
complete catch-up of weight-for-height (WHZ). From an initial
programme discharge mean WHZ of 21.96(SD 1.5), there was a
1.92(95% CI 1.76 to 2.08) z-score catch-up, bringing the surviving
group to a WHZ of 0.04(1.0), comparable to sibling controls.
Weight-for-age also improved by 1.66(95% CI 1.50 to 1.82) z-
scores to a ‘long-term’ final value of 21.77(1.1). This was,
however, significantly below that of sibling controls: mean
difference in z-scores 20.55(95% CI 20.71 to 20.38, p,0.01).
Height-for-age also improved, albeit by only 0.37(95% CI
0.21 to 0.53, p,0.01) z-scores, to a ‘long-term’ final value of
22.97(SD1.3). This was again significantly lower than that of the
sibling controls: mean difference 21.13(95% CI 21.34 to 20.93,
p,0.01). Median age of all the siblings who were measured was 61
months and median age of the ex-MOYO children who has a
sibling measured was 41 months. Further details of growth
outcomes are available online and include sibling-by-sibling
comparisons (pages 123–125) and comparisons by HIV and
admission oedema (pages 114–118) [14]. Table S2 in this paper
shows main anthropometric changes in the ex-MOYO children
over the course of the study.
Discussion
In our SAM treatment programme, overall mortality was high
in both the short and medium term, markedly above SPHERE
targets of,10% [6]. Long term survivors showed good weight-for-
height catch-up growth, some weight-for-age catch-up but
minimal height-for-age catch-up, compared to sibling controls.
These observations are rare in the SAM literature and therefore
offer key lessons for policy makers and programme managers:
First is the need for more information on longer term outcomes
so as to assess the true impact of SAM on child mortality. In our
setting, routine reporting would have given a falsely optimistic
impression of post-SAM mortality. Overall 427/1024(42%)
Table 2. Cox regression exploring main baseline predictors of death.
Risk factor Number of deaths
Hazard ratio
(95% CI)
Adjusted hazard
ratio* (95% CI) P (adj.)
Sex Girls 202/469 (43%) Ref. Ref.
Boys 221/530 (42%) 0.92 (0.76 to 1.12) 0.89 (0.73 to 1.08) 0.26
Age group (in months) .= 60 30/88 (34%) 1.11 (0.58 to 2.12) 1.22 (0.63 to 2.36) 0.55
48–,60 13/42 (31%) Ref. Ref.
36–,48 25/68 (37%) 1.27 (0.65 to 2.49) 1.66 (0.84 to 3.29) 0.14
24–,36 85/230 (37%) 1.26 (0.70 to 2.25) 1.38 (0.76 to 2.49) 0.29
12–,24 176/430 (41%) 1.42 (0.81 to 2.49) 1.57 (0.89 to 2.78) 0.12
,12 97/145 (67%) 2.89 (1.62 to 5.17) 2.49 (1.38 to 4.51) 0.002
Oedema No 205/305 (67%) Ref. Ref.
Yes 220/694 (32%) 0.37 (0.30 to 0.44) 0.58 (0.47 to 0.72) ,0.001
Mid Upper Arm Circumference Per cm unit increase 418/991 (42%) 0.70 (0.66 to 0.74) 0.80 (0.74 to 0.86) ,0.001
Weight-for-Height Per 1 unit z-score
increase
409/973(42%) 0.65 (0.60 to 0.71) 0.75 (0.68 to 0.83) ,0.001
Weight-for-Age Per 1 unit z-score
increase
425/999 (43%) 0.59 (0.54 to 0.64) 0.73 (0.66 to 0.81) ,0.001
Height-for-age Per 1 unit z-score
increase
417/989 (42%) 0.83 (0.78 to 0.89) 0.92 (0.86 to 0.99) 0.04
HIV Neg 77/459 (17%) ref ref
Pos 273/443 (62%) 4.84 (3.75 to 6.24) 4.03 (3.08 to 5.25) ,0.001
unknown 76/101 (75%) 17.8 (12.8 to 24.8) 16.9 (12.1 to 23.7) ,0.001
* Adjusted for age, oedema, and HIV status.
doi:10.1371/journal.pone.0096030.t002
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children died, but 105(25%) of these deaths occurred .90 days
after their original admission. They would have been missed by
most nutrition programmes which only follow-up patients up to
discharge from outpatient care. Other factors which can mislead
routine reporting systems but which we were able to describe
include: defaulter follow-up so as to ascribe correct survival status;
correctly capturing readmissions (of our 52 readmissions, 17(33%)
died) – if not done, denominator population is overestimated and
% mortality thus underestimated.
The second key lesson is that patient clinical profile needs to be
better accounted for, both when managing individual patients and
when judging programme performance. Simple targets like those
set by SPHERE offer useful ‘red flags’ for further investigation but
cannot alone distinguish between poorly performing programmes
and those caring for a clinically complex patient population.
Differentiating these will become increasingly important as
countries/regions develop and primary SAM due to food
insecurity alone becomes less common. A greater proportion of
affected children in such areas will have an underlying medical
condition either directly causing or significantly contributing to
SAM. Whilst our overall mortality was high, sub-analysis by HIV
status revealed that HIV infection was associated with much of the
excess mortality. We note the even higher mortality among
children whose serostatus was unknown. Too sick to be tested
Table 3. Cox regression exploring clinical and social risk factors for death, by HIV serostatus.
Risk factor (assessed at original admission) Hazard ratio for all mortality (short and long term)*
HIV negative p HIV positive p
CLINICAL RISK FACTORS
Symptoms in previous 2 weeks Fever 0.96 (0.58 to 1.58) 0.87 0.85 (0.65 to 1.12) 0.25
Diarrhoea 1.59 (0.95 to 2.68) 0.08 1.15 (0.88 to 1.51) 0.31
Vomiting 0.84 (0.52 to 1.37) 0.49 1.23 (0.96 to 1.58) 0.10
Fast or difficult breathing 1.12 (0.59 to 2.12) 0.72 0.71 (0.51 to 0.99) 0.04*
Cough 1.06 (0.65 to 1.74) 0.80 1.03 (0.79 to 1.36) 0.80
Anorexia 0.75 (0.46 to 1.22) 0.25 1.17 (0.91 to 1.51) 0.22
Flaky paint dermatosis 1.66 (0.93 to 2.96) 0.09 1.14 (0.75 to 1.72) 0.54
Anaemia Any (PCV,30) 1.08 (0.65 to 1.80) 0.76 1.05 (0.80 to 1.36) 0.73
Severe (PCV,10) 2.19 (0.66 to 7.23) 0.20 2.62 (1.18 to 5.84) 0.02*
Malaria 0.26 (0.04 to 1.88) 0.18 0.94 to 0.46 to 1.95) 0.88
Ever had TB 2.81 (0.35 to 22.7) 0.33 1.27 (0.77 to 2.09) 0.35
Disability (any) 2.77 (1.43 to 5.34) 0.002* 1.76 (0.94 to 3.28) 0.08
Not breastfed (,2 year olds only) 0.67 (0.36 to 1.26) 0.21 0.98 (0.70 to 1.38) 0.92
Inpatient episodes (non-SAM, past year) 1.03 (0.55 to 1.91) 0.94 1.31 (0.99 to 1.75) 0.06
Outpatient episodes in past 6 months 0.69 (0.34 to 1.40) 0.30 0.69 (0.40 to 1.21) 0.20
past 6 months, symptoms of SAM 1.33 (0.74 to 2.41) 0.34 1.00 (0.74 to 1.36) 1.00
SOCIAL AND ECONOMIC RISK FACTORS
Orphan Mother died 0.97 (0.35 to 2.70) 0.95 0.72 (0.45 to 1.15) 0.17
Father died 1.33 (0.52 to 3.42) 0.56 1.35 (0.84 to 2.16) 0.21
Both died 2.78 (0.92 to 8.34) 0.07 1.07 (0.47 to 2.45) 0.17
Maternal education None Ref. Ref.
Primary school 1.06 (0.53 to 2.13) 0.87 0.78 (0.51 to 1.20) 0.27
Secondary school 0.57 (0.21 to 1.54) 0.27 0.97 (0.60 to 1.57) 0.91
Paternal education None Ref. Ref.
Primary school 2.84 (0.38 to 21.26) 0.31 0.89 (0.39 to 2.04) 0.79
Secondary school 2.31 (0.30 to 17.53) 0.42 0.80 (0.35 to 1.84) 0.60
Wealth quintile Poorest Ref. Ref.
2nd poorest 1.35 (0.63 to 2.89) 0.43 0.67 (0.41 to 1.09) 0.10
Middle 1.11 (0.50 to 2.44) 0.80 0.95 (0.61 to 1.47) 0.82
2nd richest 1.49 (0.69 to 3.26) 0.31 0.93 (0.59 to 1.45) 0.75
Richest 0.95 (0.38 to 2.42) 0.92 0.91 (0.60 to 1.38) 0.66
Main household water source Piped Ref. Ref.
Borehole 0.72 (0.42 to 1.23) 0.23 0.90 (0.67 to 1.21) 0.50
Well or spring 1.09 (0.51 to 2.32) 0.83 0.90 (0.60 to 1.37) 0.63
Rural Residence 0.67 (0.39 to 1.13) 0.13 0.82 (0.62 to 1.10) 0.62
* Adjusted for oedema, age, sex, admission WAZ and admission MUAC.
doi:10.1371/journal.pone.0096030.t003
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before they died, we believe that most of this group were likely to
have been serostatus positive - if so, the known positive results in
our paper are a likely under-estimate of the true adverse impact of
HIV. Some might argue that children with HIV are therefore
better described as dying from ‘end-stage HIV disease’ (AIDS)
rather than from malnutrition with underlying HIV – but to us
such distinctions are semantic. What matters is how to better
support these children in future programmes: even with more
proactive ARV treatment programmes identifying and treating
children at an earlier stage, some will end up malnourished and
enrolled in feeding programmes such as ours. Therefore, our
results, and our message that nutrition programmes need to better
care for this especially vulnerable subgroup remains valid. This
HIV-associated risk is already well known [19],[20] but other
factors are less well described. Notable in FuSAM is the
importance of underlying disability. This affected 6% of children
and accounted for significant excess mortality - a likely underes-
timate given that we had no formal screening tool and therefore
identified only the most obvious problems. At present, few
programmes actively look for disability so this is a key area for
future work [21],[22].
The third message relates to the current international emphasis
on tackling childhood stunting, championed by the SUN (Scaling
up Nutrition) movement [23]. Our results suggest that SUN must
take SAM seriously, just as SAM treatment programme should
aim to engage more with the SUN. Current treatments for SAM
are clearly important and necessary to minimise mortality, but
may not be sufficient to address stunting on their own. Whilst it
was encouraging to observe good chances of longer term survival
following an initial nutritional cure (365/471(77%) of cures being
still alive at a year or more after their first admission), limited
improvement in survivors’ height-for-age was, however, disap-
pointing, as was their significant stunting compared to sibling
controls. This is even more notable given the siblings’ older
median age: population prevalence of stunting increases over the
first two years of life so that older cohorts might be expected to be
more rather than less stunted [24]. Whilst weight-for-age had
improved, it also remained low, significantly below siblings’. The
marked improvement of weight-for-height z-scores though in one
sense welcome, likely reflects rapid weight gain combined with
poor linear growth, a pattern which may be associated with later
obesity and chronic disease [25],[26]. This needs further study.
Strengths and consistency with other literature
Our biggest strength is duration of follow-up, at least one year,
often longer, after discharge from SAM treatment. Such longer
term outcome information is rare. Related to this, our second
major strength is a high follow-up rate – 87% is especially good for
a developing country setting. This reduces the risk of bias
associated with large numbers of ‘defaulters’, who may be deaths
[9].
FuSAM compares favourably to the few other studies looking at
longer term SAM outcomes. Most of these other studies however
took place pre-HIV [8], FuSAM thus filling a key gap, regarding
HIV-era outcomes, especially in sub Saharan Africa where the
problem is greatest [27].
In Niger in 1992 [28], of 174 discharged from a TFP, 107(61%)
were followed up. At 3–16 months follow-up 17% had died.
Though compared to FUSAM this appears better, there is much
larger probability of bias due to 39% unknown outcome, a
proportion of whom may have been deaths. In Zaire in 1987 [29],
171 SAM children discharged from hospital were followed up and
81.6% found still alive at the end of 5 years. However, kwashiorkor
in that study was mainly based on serum albumin and some of the
children classified as such might not have met today’s oedema,
WFH, or MUAC criteria for SAM. In Tanzania in 1987, 87% of
566 children who had been discharged from an NRU were
followed over a year [30]. The mortality after discharge was 8%
and relapse rate was 13%. In a retrospective cohort study in
Guinea Bissau, 1995 [31], 1038 severely malnourished children
(defined by weight-for-age ,60% NCHS standards) were followed
up over 3 years. 354 had received nutritional rehabilitation
whereas 684 did not, due to limited programme capacity. Up to 3
years, the relative risk of death in the rehabilitated group was
0.75(0.59 to 0.99). The mortality difference was greatest in the first
three months. Weight-for-age z-scores improved from a baseline of
24.52 to 22.76. This is consistent with the weight-for-age
improvements we observed in FuSAM.
Weaknesses and generalizability
We acknowledge the limitations of our study so hope that it will
inspire more detailed future work to address these:
FuSAM was conducted when CMAM (Community Manage-
ment of Acute Malnutrition) was not as widespread as it is today. It
was not available in Blantyre district where we worked (though it
did start shortly after, in mid-2008). This public health orientated
approach to SAM treats children mainly as outpatients [2], and
emphasises proactive identification through community screening,
rather than reactive detection during hospital visits as we had at
the time of FuSAM [7]. Even though some risk factors for
mortality (e.g. HIV, disability) are likely to be found in both
settings, care is needed before generalising our findings to CMAM
programmes. However, our results are consistent with CMAM’s
key principle that earlier treatment is better [7] (i.e. the less severe
the malnutrition at baseline, the better the chances of survival).
This has recently been confirmed in a follow-up of a CMAM
cohort [8], also from Malawi showing much better outcomes than
ours. Given this context, our paper is a clear call to any
programmes which have not yet switched from inpatient-only
SAM care to CMAM, to do so. Whilst in many ways a typical
resource poor developing country setting, MOYO ward at the
time of FuSAM had inputs and resources (in terms of staff time,
clinical expertise, continuity of drug, food and equipment supplies)
far above the vast majority of TFPs in Malawi and elsewhere in
Sub-Saharan Africa. If our outcomes were poor, they are likely
even worse in most other, less well supported settings.
Figure 4. Boxplot showing weight-for-height, weight-for-age
and height-for-age of the ex-malnourished surviving child (M)
(n=386) compared to sibling controls (S) (n =277).
doi:10.1371/journal.pone.0096030.g004
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Another limitation related to generalizability is that we
examined patients already enrolled in SAM treatment. In-
programme risk factors such as we observed are not necessarily
the same as those at population-level. Even if a particular risk
factor (e.g. HIV infection) is relevant to both general population
and within-programme children, the magnitude of effect is likely to
be different.
Related to the lack of obvious ‘impact’ of factors like
socioeconomic status (SES), we also acknowledge that we did
not model all the possible causal pathways. For instance, low SES
could cause/contribute to low admission anthropometry, which
did adversely affected outcomes. Hence adjusting for anthropo-
metric status might have concealed the impact of SES. Such
pathways need exploration in future work
Resource limitations meant that we were not able to follow-up
regularly at fixed time-points after programme discharge, but
instead relied on a single long term FuSAM visit. It is possible that
some variables such as socioeconomic status or orphaning may
have changed over time and hence we may have missed their
effects.
Next, is the possibility of systematic reporting or recall bias. We
cannot exclude this but do not believe that it is a major problem
since death is a very objective outcome, with major findings such
as those concerning HIV and disability all highly plausible
biologically as well as themselves objective/backed by recorded
blood test in case of HIV. We also cannot be sure how missing
data from the 13% of children lost to follow-up might have
affected results - though as previously stated this is good for a
developing country setting so we do not believe it would have
significantly altered our key results or affected conclusions. More
of a problem is the increased data ‘noise’ inherent to some of the
more subjective, self-reported variables such as socioeconomic
status: small but real risks may have been obscured. Another issue
is potential selection bias of children seen in the hospital admission
departments, before arrival at the MOYO nutrition ward. Very
sick patients might die in the admissions area or on the special care
ward before transfer to MOYO. Borderline cases might be missed
and wrongly sent to the normal paediatric wards instead of to
MOYO.
The last potential limitation of our study relates to seasonal
variations in the risk of malnutrition. Though recruitment was
spread over most of a year and captured both rainy (hungry)
season and dry (post-harvest) seasons, there may have been
variations in nutritional status depending on when a child was
admitted and followed up. Logistic constraints led to variations in
time to follow-up. Had a constant time been possible, perhaps
different magnitudes of z-score change might have been observed.
Again, we doubt that the overall pattern of findings would have
been very different. One of the advantages of using sibling controls
was that they were measured at the same time as the ex-MOYO
child. Where differences were seen they cannot therefore be
ascribed solely to seasonal variations.
Conclusions and implications for policy and
practice
Although this is an observational study, we believe that our
findings have strong policy and practice implications.
The first is the need to be much more aware of longer term as
well as short term outcomes of SAM. This long term perspective
will also help focus attention on important non-mortality outcomes
such as growth, development, co-morbidities and pre-determi-
nants for eventual adult non-communicable disease.
Second is that a more holistic view of SAM management is
needed. Treatment is not just about food - this is necessary but not
alone sufficient. Programmes should work closer in collaboration
with other child health services and form part of a seamless
‘continuum of care’. Many SAM treatment programmes already
appreciate the need for close links with HIV-related services [32]
but the need to improve outcomes for children with disability (and
likely other) chronic underlying disease is also clear from our
results. Urgent future work is needed to elaborate exactly which
interventions are most effective and most cost-effective for these
vulnerable individuals.
Finally, our results support calls for on early identification and
treatment of SAM. The pioneers of CMAM stressed community
engagement and active case finding to identify and treat SAM as
early as possible [33],[34]. This emphasis has not always been
maintained in subsequent programmes documents [2]. Now is the
time for this message to be re-vitalised in all SAM programming
[7]. Whilst other confirmatory research is urgently needed, it is
very plausible that earlier treatment of SAM would favourably
affect stunting and longer term post-SAM chronic disease – both
key areas in current international malnutrition policy and
programming. Proactive SAM treatment services are essential.
They not only have great potential to reduce mortality in the short
term but also great potential to impact on longer term morbidity
consequences.
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